title: Combination of acarbose and ezetimibe prevents non-alcoholic fatty liver disease: a break of intestinal insulin resistance?
authors.forename: Natalia N
authors.initials: NN
authors.lastname: Rudovich
authors.forename: Martin O
authors.initials: MO
authors.lastname: Weickert
authors.forename: Juergen
authors.initials: J
authors.lastname: Machann
authors.forename: Andreas F H
authors.initials: AF
authors.lastname: Pfeiffer
mesh_terms: D020909:Acarbose / Q000008:administration & dosage*; D000924:Anticholesteremic Agents / Q000008:administration & dosage*; D001384:Azetidines / Q000008:administration & dosage*; D004359:Drug Therapy, Combination; D000069438:Ezetimibe; D005234:Fatty Liver / Q000188:drug therapy / Q000378:metabolism / Q000517:prevention & control*; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage*; D007333:Insulin Resistance
chemical_list: D000924:Anticholesteremic Agents; D001384:Azetidines; D007004:Hypoglycemic Agents; D000069438:Ezetimibe; D020909:Acarbose